Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.

MLA

Hardwick, Rhiannon N., et al. “Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.” Toxicological Sciences : An Official Journal of the Society of Toxicology, vol. 186, no. 2, Mar. 2022, pp. 323–37. EBSCOhost, https://doi.org/10.1093/toxsci/kfac002.

APA

Hardwick, R. N., Brassil, P., Badagnani, I., Perkins, K., Obedencio, G. P., Kim, A. S., Conner, M. W., Bourdet, D. L., & Harstad, E. B. (2022). Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species. Toxicological Sciences : An Official Journal of the Society of Toxicology, 186(2), 323–337. https://doi.org/10.1093/toxsci/kfac002

Chicago

Hardwick, Rhiannon N, Patrick Brassil, Ilaria Badagnani, Kimberly Perkins, Glenmar P Obedencio, Andrea S Kim, Michael W Conner, David L Bourdet, and Eric B Harstad. 2022. “Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.” Toxicological Sciences : An Official Journal of the Society of Toxicology 186 (2): 323–37. doi:10.1093/toxsci/kfac002.